Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma.

Like Comment
Bromodomain and extra-terminal (BET) proteins are epigenetic readers that regulate expression of genes involved in oncogenesis. CC-90010 is a novel, oral, reversible, small-molecule BET inhibitor.CC-90010-ST-001 (NCT03220347; 2015-004371-79) is a phase I dose-escalation and expansion study of CC-90010 in patients with advanced or unresectable solid tumors and relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). We report results from the dose escalation phase, which explored 11 dose levels and 4 dosing schedules, 2 weekly [2 days on/5 days off; 3 days on/4 days off], 1 biweekly [3 days on/11 days off], and 1 monthly [4 days on/24 days off]). Primary objectives were to determine the safety, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and schedule. Secondary objectives were to evaluate signals of early anti-tumor activity, pharmacokinetics, and pharmacodynamics.This study enrolled 69 patients, 67 with solid tumors and 2 with diffuse large B-cell lymphoma (DLBCL). Median age was 57 years (range, 21-80) and median number of prior regimens was 4 (range, 1-9). Treatment-related adverse events (TRAEs) were mostly mild and manageable; grade 3/4 TRAEs reported in >2 patients were thrombocytopenia (13%), anemia, and fatigue (4% each). Six patients had dose-limiting toxicities. MTDs were 15 mg (2 days on/5 days off), 30 mg (3 days on/11 days off), and 45 mg (4 days on/24 days off). The RP2D and schedule selected for expansion was 45 mg (4 days on/24 days off). As of October 8, 2019, 1 patient with grade 2 astrocytoma achieved a complete response, 1 patient with endometrial carcinoma had a partial response, and 6 patients had prolonged stable disease ≥11 months.CC-90010 is well-tolerated, with single-agent activity in patients with heavily pretreated, advanced solid tumors.

Click here to read the full article @ Annals of oncology : official journal of the European Society for Medical Oncology
Go to the profile of ClinOwl


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
2212 Contributions
0 Following

No comments yet.